1
|
Ncube BM, Dube A, Ward K. The process of ratifying the treaty to establish the African Medicines Agency: perspectives of national regulatory agencies. Health Policy Plan 2024; 39:447-456. [PMID: 38497780 PMCID: PMC11095264 DOI: 10.1093/heapol/czae017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2023] [Revised: 12/23/2023] [Accepted: 03/13/2024] [Indexed: 03/19/2024] Open
Abstract
The vision of the African Medicines Agency (AMA) is to ensure that all Africans have access to affordable medical products that meet internationally recognized standards of quality, safety and efficacy for priority diseases/conditions. The AMA is being established by a treaty which had to be ratified by a minimum of 15 African countries. Although there was no deadline, the ratification process has been slower than expected. This study therefore analysed the rationale, perceived benefits, enabling factors and challenges of the AMA's establishment. This study was a qualitative, cross-sectional, census survey of the national medicines regulatory authorities (NRAs) of 45 African countries. The Heads of NRAs and a senior NRA staff member were contacted to complete self-administered questionnaires. The existence of mature NRAs, the desire to have harmonized regulatory systems, the presence of strong political will and appropriate advocacy to expedite treaty signing are all enabling factors for AMA treaty signing. The challenges reported include the fact that the process is slow and there is limited understanding of the process. Competing national priorities, changes in office bearers in the public system and stagnation of the process at the ministerial level were also challenges reported. This study has improved the understanding of the treaty signing and ratification process and the perceived benefits and enabling factors of signing and ratification from African NRAs' perspective. NRAs also highlighted challenges encountered in the process. Addressing these challenges will result in effective medicines regulation by galvanizing technical support, regulatory expertise and resources at a continental level.
Collapse
Affiliation(s)
- Bakani Mark Ncube
- School of Pharmacy, University of the Western Cape, Private Bag X17, Bellville 7535, South Africa
| | - Admire Dube
- School of Pharmacy, University of the Western Cape, Private Bag X17, Bellville 7535, South Africa
| | - Kim Ward
- School of Pharmacy, University of the Western Cape, Private Bag X17, Bellville 7535, South Africa
| |
Collapse
|
2
|
Alfonso CP, N’Jambong GB, Magdy A, Di Trapani L, Kuwana R, Kahsay AG, Maïga D, Ossei-Agyeman-Yeboah SNA, Djitafo Fah AB, Ndomondo-Sigonda M. Identifying and costing common gaps in Central and West Africa pharmaceutical regulation. Front Med (Lausanne) 2024; 11:1362253. [PMID: 38660423 PMCID: PMC11042247 DOI: 10.3389/fmed.2024.1362253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2023] [Accepted: 02/19/2024] [Indexed: 04/26/2024] Open
Abstract
Background Regulatory systems strengthening is crucial for catalyzing access to safe and effective medical products and health technologies (MPHT) for all. Identifying and addressing common regulatory gaps through regional approaches could be instrumental for the newly incepted African Medicine Agency. Aims This original study sheds light on common gaps among 10 national regulatory authorities (NRAs) and ways to address them regionally. Objectives The study used NRA self-assessment outcomes to identify common gaps in four critical regulatory pillars and estimate the cost of addressing them from regional perspectives that aimed at raising the maturity level of regulatory institutions. Methods A cross-sectional study, using the WHO Global Benchmarking Tool (GBT), was conducted between 2020 and 2021 with five NRAs from ECCAS and ECOWAS member states that use French and Spanish as lingua franca. Results The 10 NRAs operated in a non-formal-to-reactive approach (ML1-2), which hinders their ability to ensure the quality of MPHT and respond appropriately to public health emergencies. Common gaps were identified in four critical regulatory pillars-good regulatory practices, preparedness for public health emergencies, quality management systems, and substandard and falsified medical products-with overall cost to address gaps estimated at US$3.3 million. Contribution We elaborated a reproducible method to strengthen regulatory systems at a regional level to improve equitable access to assured-quality MPHT. Our bottom-up approach could be utilized by RECs to address common gaps through common efforts.
Collapse
Affiliation(s)
- Claudia P. Alfonso
- Regulatory Systems Strengthening, World Health Organization, Geneva, Switzerland
| | - Guy B. N’Jambong
- Essential Drug and Medicines, World Health Organization, Dakar, Senegal
- ICN Business School, CEREFIGE, Université de Lorraine, Nancy, France
| | - Alaa Magdy
- Regulatory Systems Strengthening, World Health Organization, Geneva, Switzerland
| | - Laura Di Trapani
- Regulatory Systems Strengthening, World Health Organization, Geneva, Switzerland
| | - Rutendo Kuwana
- Incident and Substandard and Falsified, World Health Organization, Geneva, Switzerland
| | - Abraham G. Kahsay
- Regulatory Convergence and Networks, World Health Organization, Geneva, Switzerland
| | - Diadié Maïga
- Regulatory Systems Strengthening, World Health Organization, Geneva, Switzerland
| | | | - Aimé B. Djitafo Fah
- Sub-Regional Program for the Harmonization of National Pharmaceutical Policies in Central Africa, Coordination Organization for the Fight Against Endemic Diseases in Central Africa, Yaoundé, Cameroon
| | - Margareth Ndomondo-Sigonda
- African Medicines Regulatory Harmonization Initiative, African Union NEPAD Agency, Pretoria, South Africa
| |
Collapse
|
3
|
Narsai K, Masekela FB, Leufkens HGM, Mantel-Teeuwisse AK. Outer packaging labelling of medicines in Southern African Development Community (SADC) countries: comparative analysis of requirements and transition terms for harmonisation. BMC Health Serv Res 2024; 24:111. [PMID: 38245720 PMCID: PMC10799382 DOI: 10.1186/s12913-024-10585-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Accepted: 01/09/2024] [Indexed: 01/22/2024] Open
Abstract
INTRODUCTION The COVID-19 pandemic highlighted an urgent need for harmonised requirements for the regulation of medicines. To fully implement harmonised medicines regulations across Africa, common technical standards of medicine regulations are needed. One such technical standard is the labelling of medicines on outer packaging. In this study, we compared outer packaging labelling requirements and transition terms for harmonization for countries in the Southern African Development Community (SADC) region. METHODS Data on legislation and/or regulatory guidelines for medicine outer packaging labelling from National Medicines Regulatory Authorities (NMRAs) were obtained for countries in the SADC region (n = 16) by February 2023. A detailed comparative content analysis was conducted to determine alignment with the requirements of the Southern African Development Community (SADC) harmonised labelling guidelines to assess readiness levels of each country to transition to the SADC harmonised labelling guideline for outer packaging of medicines. RESULTS Content analysis showed at least 11 out of 16 countries require national legal reform to transition to the SADC harmonised labelling guideline. In all cases where countries specified labelling requirements for outer packaging of medicines, these were stipulated in national medicines legislation. CONCLUSION Even though there is a high level of alignment across the countries in terms of national labelling requirements, most countries in the SADC region would still require national legislative reform to transition to regional harmonised labelling requirements and then ultimately to continental requirements of the African Medicines Agency (AMA).
Collapse
Affiliation(s)
- K Narsai
- Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands
- Nelson Mandela School of Public Governance, Cape Town, South Africa
| | - F B Masekela
- Medicines Control Authority of Zimbabwe (MCAZ), Harare, Zimbabwe
| | - H G M Leufkens
- Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands
| | - A K Mantel-Teeuwisse
- Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands.
| |
Collapse
|
4
|
Wasan H, Reeta KH, Gupta YK. Strategies to improve antibiotic access and a way forward for lower middle-income countries. J Antimicrob Chemother 2024; 79:1-10. [PMID: 38008421 DOI: 10.1093/jac/dkad291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2023] Open
Abstract
Antibiotics have substantially improved life expectancy in past decades through direct control or prevention of infections. However, emerging antibiotic resistance and lack of access to effective antibiotics have significantly increased the death toll from infectious diseases, making it one of the biggest threats to global health. Addressing the antibiotic crisis to meet future needs require considerable investment in both research and development along with ensuring a viable marketplace to encourage innovation. Fortunately, there has been some improvement in the number of antibiotics approved or in different phases of development through collective global efforts. However, the universal access to these essential novel and generic antibiotics, especially in low- and middle-income countries (LMICs), is challenged by poor economic incentives, regulatory hurdles and poor health infrastructure. Recently, the agenda of securing and expanding access has gained global attention. Several mechanisms are now being proposed and implemented to improve access to essential antibiotics. This review provides an insight into the major barriers to antibiotic access as well as the models proposed and implemented to mitigate accessibility issues. These models include but are not limited to market entry rewards, subscription models and transferable exclusivity vouchers. Further, global access programmes including, Global Antibiotic Research and Development Partnership, Antimicrobial Resistance Action Fund and SECURE Platform are discussed. We also propose the way forward for improving access in LMICs with suggested measures to improve access to generic and novel antibiotics.
Collapse
Affiliation(s)
- Himika Wasan
- Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India
| | - K H Reeta
- Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India
| | - Yogendra Kumar Gupta
- All India Institute of Medical Sciences, Jammu, India
- India Strategy Development, Global Antibiotics Research & Development Partnership (GARDP), New Delhi, India
| |
Collapse
|
5
|
Ngum N, Ndomondo-Sigonda M, Walker S, Salek S. Regional regulatory harmonisation initiatives: Their potential contribution to the newly established African Medicines Agency. Regul Toxicol Pharmacol 2023; 145:105497. [PMID: 37778434 DOI: 10.1016/j.yrtph.2023.105497] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Revised: 08/22/2023] [Accepted: 09/28/2023] [Indexed: 10/03/2023]
Abstract
BACKGROUND Key regulatory entities can serve as building blocks for the African Medicines Agency (AMA). The aim of this study is to demonstrate how the regional medicines regulatory harmonisation programmes could contribute to AMA's effectiveness and efficiency. METHODS A literature search was conducted using key words to identify publications about the AMA, African Medicines Regulatory Harmonisation (AMRH) and East African Community Medicines Regulatory Harmonisation programmes (EAC-MRH) from 2009 to 2023. The EAC-MRH programme experience was used to highlight the benefits and challenges of African regulatory harmonisation. RESULTS As the foundation for the AMA, the AMRH has established structures and workstreams to support its operationalisation, including 10 Technical Committees (TCs) and 5 Regional Economic Committees (RECs). Lessons learned from the EAC-MRH 10-year experience are being used to scale up regulatory harmonisation and could be of value to AMA harmonisation experience. CONCLUSIONS As of June 2023, 35 of 55 countries have either signed and/or ratified the AMA Treaty, whilst 20 have neither signed nor ratified it. An effective AMA will need strong National Medicines Regulatory Authorities as well as Regional programmes and it is imperative for more well-resourced countries to ratify the treaty to ensure access to essential medical products and technologies for the African people.
Collapse
Affiliation(s)
- Nancy Ngum
- Department of Clinical and Pharmaceutical Sciences, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom; African Union Development Agency - New Partnership for Africa's Development (AUDA-NEPAD), Johannesburg, South Africa
| | - Margareth Ndomondo-Sigonda
- African Union Development Agency - New Partnership for Africa's Development (AUDA-NEPAD), Johannesburg, South Africa
| | - Stuart Walker
- Department of Clinical and Pharmaceutical Sciences, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom; Centre for Innovation in Regulatory Science, London, United Kingdom
| | - Sam Salek
- Department of Clinical and Pharmaceutical Sciences, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom; Institute of Medicines Development, Cardiff, United Kingdom.
| |
Collapse
|
6
|
Miletic N, Adam S, Acquah J, Aziz Z, Joos A, Mwangi JM. What makes joint assessment procedures attractive to the innovative industry: successes, challenges, and proposed improvements. Front Med (Lausanne) 2023; 10:1207954. [PMID: 37731723 PMCID: PMC10507468 DOI: 10.3389/fmed.2023.1207954] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2023] [Accepted: 08/16/2023] [Indexed: 09/22/2023] Open
Abstract
Regulatory harmonization and convergence have been identified as the key driver in promoting efficient evaluation of medicines, reducing workload, and supporting earlier access to medicines on the African continent. There has been great progress to date in enhancing regulatory harmonization and convergence on the African continent via the Regional Economic Communities (RECs) and with the establishment of the Africa Medicines Agency (AMA). In this article, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Africa Regulatory Network (ARN) presents its perspective based on the available literature review and results from a survey conducted with innovative biopharmaceutical companies to gather experiences using regional joint assessment procedures (JAPs) in Africa, such as the East African Community Medicines Regulatory Harmonization (EAC-MRH), the West African Medicines Regulatory Harmonization (WA-MRH), and the Southern African Development Community Medicines Regulatory Harmonization (SADC-MRH) initiative through the ZAZIBONA Collaborative Procedure for Medicines Registration (ZaZiBoNa), and provides best practices in this evolving landscape. The article also assesses other collaborative registration pathways available to facilitating registration of pharmaceutical products in African countries, such as WHO Collaborative Registration Procedures (CRP), Swissmedic's Marketing Authorisation for Global Health Products (MAGHP) and EU Medicines for All (EU-M4ALL). Benefits and challenges of each of the existing pathways are discussed in this article. Main benefits include building more expert capacity and improved collaboration amongst experts, as well as shorter review timelines in some cases. Key challenges include the lack of predictability in the adherence to procedural timelines as defined per guidelines, lengthy timeline to achieve national marketing authorization following joint assessment, the lack of dedicated personnel, administrative issues during the submission process as well as additional country-specific requirements on top of JAP-specific requirements. Our recommendations for improvements include harmonization of requirements across countries and regions and with international standards, appropriate resource allocation for JAP activities to ensure adherence to timelines, use of JAPs throughout the entire product lifecycle and all product categories, adequate use of digital technologies, and improved communication and transparency with applicants. These improvements will allow industry to better plan their filing strategies for the region which will lead to overall improved usability of the JAPs in Africa and enable faster patient access.
Collapse
Affiliation(s)
| | - Sarah Adam
- The International Federation of Pharmaceutical Manufacturers and Associations, Geneva, Switzerland
| | | | - Zainab Aziz
- Novartis South Africa (Pty) Ltd, Magwa Crescent West, Johannesburg, South Africa
| | | | | |
Collapse
|
7
|
Khalil R, Macdonald JC, Gustafson A, Aljuburi L, Bisordi F, Beakes-Read G. Walking the talk in digital transformation of regulatory review. Front Med (Lausanne) 2023; 10:1233142. [PMID: 37564043 PMCID: PMC10411640 DOI: 10.3389/fmed.2023.1233142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Accepted: 06/20/2023] [Indexed: 08/12/2023] Open
Abstract
Cloud-based regulatory platforms have the potential to substantially transform how regulatory submissions are developed, transmitted, and reviewed across the full life cycle of drug development. The benefits of cloud-based submission and review include accelerating critical therapies to patients in need globally and efficiency gains for both drug developers and regulators. The key challenge is turning the theoretical promise of cloud-based regulatory platforms into reality to further the application of technology in the regulatory processes. In this publication we outline regulatory policy journeys needed to effect the changes in the external environment that would allow for use of a cloud-based technology, discuss the prerequisites to successfully navigate the policy journeys, and elaborate on future possibilities when adoption of cloud-based regulatory technologies is achieved.
Collapse
|
8
|
McAuslane N, Bujar M, Sithole T, Ngum N, Owusu-Asante M, Walker S. Evaluation of Risk-Based Approaches to the Registration of Medicines: Current Status Among African Regulatory Authorities. Pharmaceut Med 2023; 37:251-260. [PMID: 37074548 PMCID: PMC10113993 DOI: 10.1007/s40290-023-00472-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/12/2023] [Indexed: 04/20/2023]
Abstract
BACKGROUND Despite the worldwide need for increased access to safe and effective medicines, there is a lack of innovative medicines in many low- to middle-income countries. On the African continent, this is partly due to capacity limitations of National Regulatory Authorities (NRAs). One important approach to address this issue is work sharing and regulatory reliance. Therefore, the aim of this study of regulatory authorities on the African continent was to identify which risk-based approaches are being used as well as their foreseen role in the future. METHODS The study employed a questionnaire to identify which risk-based models are used for the regulatory approval of medicines and to determine which frameworks are in place to enable a risk-based approach, as well as to provide insight into the future direction for risk-based models. The questionnaire was sent electronically to 26 NRAs in the African Continent. RESULTS Twenty-one authorities (80%) completed the questionnaire. Work sharing was the most commonly used model, followed closely by unilaterial reliance, information sharing, and collaborative review. These methods were perceived to be an effective and efficient use of resources, enabling faster medicine availability for patients. The unilateral reliance approach by the authorities included abridged (85%), verification (70%) and recognition (50%) models for a range of products. However, challenges included a lack of guidelines to undertake a reliance review together with resource constraints, while access to assessment reports was the most common barrier to using a unilateral reliance model. CONCLUSIONS Many authorities in Africa have adopted a risk-based approach to medicines registration and created work sharing, unilateral reliance pathways and regionalisation models to facilitate the availability of medicines. The authorities believe that in future, assessment routes should move from stand-alone reviews to risk-based models. However, this study indicated that there would be challenges to implement this approach in practice, which would include improving resource capacity and the number of expert reviewers as well as implementing electronic tracking systems.
Collapse
Affiliation(s)
- Neil McAuslane
- Centre for Innovation in Regulatory Science, 70 St Mary Axe, London, UK
| | - Magda Bujar
- Centre for Innovation in Regulatory Science, 70 St Mary Axe, London, UK
| | - Tariro Sithole
- Medicines Control Authority of Zimbabwe, Harare, Zimbabwe
| | - Nancy Ngum
- African Union Development Agency-New Partnership for Africa's Development (AUDA-NEPAD), Johannesburg, South Africa
| | | | - Stuart Walker
- Centre for Innovation in Regulatory Science, 70 St Mary Axe, London, UK.
| |
Collapse
|
9
|
Mpanza NM, Godman B, Keele MG, Matlala M. Trends in the utilization of medicines sold in the private sector post- registration in South Africa and the implications for similar countries. BMC Public Health 2023; 23:192. [PMID: 36709246 PMCID: PMC9884155 DOI: 10.1186/s12889-023-15021-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2022] [Accepted: 01/10/2023] [Indexed: 01/29/2023] Open
Abstract
BACKGROUND Regulatory authorities register medicines for patients to access them within a reasonable period of time. There is a paucity of available data regarding the extent to which registered medicines reach the public after market authorisation is granted by the South African Health Products Regulatory Authority (SAHPRA). This is important since time spent by SAHPRA assessing medicines that are subsequently not launched onto the South African market means time wasted, which could be spent on assessing new medicines that address an unmet need in the country. Consequently, we initially analysed the time taken for registered medicines to reach patients and the relationship between medicines registered at SAHPRA and those subsequently dispensed in private pharmacies. The extent of registration of multiple sourced versus new patented medicines was also explored. METHODS A retrospective, descriptive and quantitative investigation was conducted for medicines registered between 2014 and 2019. Registered and dispensed medicines were compared to establish accessibility post registration. Data sources included SAHPRA and IQVIA datasets. Microsoft Excel and SAS were used for data storage, analysis, and computation of descriptive statistical analysis. RESULTS Of (N = 2175) registered medicines, only 358 (16.5%; 95% CI 15.0%-18.1%) were dispensed to patients, and out of 1735 medicines registered between 2015 and 2019, only 57 (3.3%; 95% CI 2.5%-4.2%) were dispensed during the study period. Medicines acting on the central nervous system were registered and dispensed the most at 21.0% and 18.0%, respectively, whereas antineoplastic and immunomodulation agents were registered and dispensed only 11% and 5%, respectively. A concern was that only 13.0% of registered medicines were originators, with most either as generics, including branded generics, or pseudo-generics. CONCLUSION Regulatory measures should be implemented to ensure increased medicine access post-registration for new originators, especially for priority disease areas that benefit patients. Mental health diseases and improved access to oncology medicines require special attention and further investigation in South Africa.
Collapse
Affiliation(s)
| | - Brian Godman
- grid.459957.30000 0000 8637 3780Present Address: School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa ,grid.11984.350000000121138138Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, G4 0RE UK ,grid.444470.70000 0000 8672 9927Centre of Medical and Bio-Allied Health Sciences Research (CMBHSR), Ajman University, Ajman, United Arab Emirates
| | - Mothobi Godfrey Keele
- grid.459957.30000 0000 8637 3780Present Address: School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa ,grid.11951.3d0000 0004 1937 1135Department of Pharmacy and Pharmacology, University of the Witwatersrand, Johannesburgh, South Africa
| | - Moliehi Matlala
- grid.459957.30000 0000 8637 3780Present Address: School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa
| |
Collapse
|
10
|
Makhene NL, Steyn H, Vorster M, Lubbe MS, Burger JR. Development of a checklist for the assessment of pharmacovigilance guidelines in Southern Africa: a document review. Ther Adv Drug Saf 2023; 14:20420986221143272. [PMID: 36713000 PMCID: PMC9880583 DOI: 10.1177/20420986221143272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2022] [Accepted: 11/15/2022] [Indexed: 01/26/2023] Open
Abstract
Introduction National regulatory systems in Southern Africa reflect various stages of maturity, and pharmacovigilance (PV) practices are not aligned. In the absence of guidance for formulating PV guidelines in Southern African Development Community (SADC) countries, this study aimed to create a checklist that may be used to assess the rigour of PV guidelines in this region and provide guidance for the National Medicines Regulatory Agency (NMRA) authors. Methods A document analysis was performed based on harmonised international guidelines (n = 22) that prescribed methods of PV regulation to identify themes and items to incorporate into a checklist. The contextualisation of the checklist to the African pharmaceutical environment was accomplished by referencing peer-reviewed journal articles (n = 7). The checklist was subjected to face and content validation by non-experts and PV experts. Results The document review yielded 5 themes, 18 sub-themes, and 73 items structured into the checklist. Themes encompassed PV systems, definitions, individual case safety reporting, aggregate reporting, and risk management. Under PV systems, aspects of the quality management system were outlined, that is, the legal basis for PV, a description of the marketing authorisation holder's (MAH's) PV system, archiving of data, contracting of PV tasks, and the duties of the person responsible for the MAH's PV obligations. Definitions of the key terms and major stakeholders were identified. Reporting of individual case safety reports (ICSRs) was explicated by considering the criteria for reporting, categories of reportable information, expedited reporting requirements, reporting timelines, and ICSR reporting format. Aggregate report submission during the development and post-marketing phases was addressed. Risk management encompassed signal detection, re-evaluation of the benefit-risk ratio, the safety decision-making process, risk management planning, risk minimisation and safety communication. Conclusion The developed checklist can contribute towards assisting SADC NMRAs to formulate national PV guidelines that reflect current international practice, with local context incorporated. Plain Language Summary Developing a checklist for the evaluation of medicine safety guidelines in Southern Africa Introduction: In Southern African Development Community (SADC) countries, the guidelines for medicine safety [pharmacovigilance (PV)] that marketing authorisation holders (MAHs) and healthcare professionals need to adhere to, are not aligned. We saw the need to develop a checklist that can be used to evaluate these guidelines.Methods: We studied international documents issued by the World Health Organization (WHO), the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), the Council for International Organizations of Medical Sciences (CIOMS) and the European Medicines Agency (EMA). On the organisational websites, we obtained 22 documents and identified 73 checklist items. All the items were arranged under 5 themes and 18 sub-themes to create the checklist. We adapted the checklist to the local context by using seven journal articles addressing PV concerns in Africa. Experts checked the content and usability of the checklist.Results: The themes were PV systems, definitions, individual case safety reporting (ICSR), combined reporting and risk management. PV systems had six sub-themes: legal structure, description of the MAH's PV system, contractual agreements, information storage, the qualified person responsible for PV (QPPV) and where the QPPV is located. We included the definitions of keywords and role-players. The ICSR theme had five sub-themes, i.e. criteria for reporting, categories of reportable information, expedited reporting, reporting timelines, and reporting format. Submission of summary reports comprised an overview of the safety profile of a medicine once it is approved by regulators, as well as during clinical trials. Risk management included signal detection, re-evaluation of the benefit-risk ratio, safety decision-making process, risk management planning, risk minimisation, and safety communication. The checklist is applied by allocating yes/no scoring per item.Conclusion: The checklist may be used by regulators within SADC to assess their PV guidelines for alignment with international standards and suitability to the local environment.
Collapse
Affiliation(s)
- Nokuthula L. Makhene
- Medicine Usage in South Africa, Faculty of
Health Sciences, North-West University, Potchefstroom, South Africa
| | - Hanlie Steyn
- Medicine Usage in South Africa, Faculty of
Health Sciences, North-West University, Potchefstroom, South Africa
| | - Martine Vorster
- Medicine Usage in South Africa, Faculty of
Health Sciences, North-West University, Potchefstroom, South Africa
| | - Martie S. Lubbe
- Medicine Usage in South Africa, Faculty of
Health Sciences, North-West University, Potchefstroom, South Africa
| | | |
Collapse
|
11
|
Mudyiwenyama LG, Khoza S, Dube A. Situation analysis on the regulation of nanomedicines in Southern Africa. Front Med (Lausanne) 2023; 10:1098830. [PMID: 37153083 PMCID: PMC10157474 DOI: 10.3389/fmed.2023.1098830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2022] [Accepted: 03/22/2023] [Indexed: 05/09/2023] Open
Abstract
Background Medical products incorporating nanoparticle drug delivery systems (nanomedicines) are therapeutic or imaging agents, which comprise a delivery system within the nanometer size range (1 - 1000 nm). As medical products, nanomedicines meet definitions of medicines according to various national legislations for regulation of medicines. However, for the regulation of nanomedicines, additional assessments including toxicological issues have to be considered. These complexities require extra regulatory effort. In the resource-limited context of low- and middle-income countries, many National Medicines Regulatory Authorities (NMRAs) lack resources and capacities to effectively assure the quality of medicinal products in their countries. With emerging trends in innovative technologies, including nanotechnology, this burden is worsened. The need to overcome regulatory challenges drove the formation of a work sharing initiative in the Southern African Development Community (SADC), ZaZiBoNA in 2013. Regulatory agencies participating in this initiative cooperate in the assessment of applications for registration of medicines. Methods A cross-sectional exploratory study design with qualitative techniques was used to investigate the status of the regulation of nanomedicines in Southern African countries in particular those participating in the ZaZiBoNA initiative. Results The study found that in general, NMRAs are aware of the existence of nanomedicines and they apply legislation applicable to other medical products. The NMRAs however neither have specific definition for nanomedicines and technical guidance documents, nor technical committees specific for consideration of nanomedicines. Collaboration with external experts or organisations in the regulation of nanomedicines was also found to be lacking. Discussion Capacity building and collaboration in the area of regulation of nanomedicines is strongly encouraged.
Collapse
|
12
|
Shabangu PP, Kuwana RJ, Dube A. Collaborative reliance in medicine safety and quality regulation: Investigation of experiences in handling N-nitrosamine impurities among ZaZiBoNa participating countries. Front Med (Lausanne) 2022; 9:975032. [PMID: 36160156 PMCID: PMC9500151 DOI: 10.3389/fmed.2022.975032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2022] [Accepted: 08/23/2022] [Indexed: 12/03/2022] Open
Abstract
Introduction The presence of N-nitrosamine impurities in medicines raised concerns globally as they are genotoxic and probable human carcinogens. A review of N-nitrosamine impurities in medicines provides an opportunity for National Regulatory Authorities (NRAs) to ensure that corrective and preventive actions are applied so that safe and good quality medicines are made available to the public. This study aimed to investigate the experiences on reviews conducted by NRAs from various Southern African Development Community countries which participate in the regional work-sharing forum, ZaZiBoNa, on the quality and safety data due to the presence of N-nitrosamine impurities in medicines. Methods A comparative, descriptive study using mixed methods was conducted. Purposive sampling was applied in selecting research participants based on their participation status in the ZaZiBoNa initiative. A standardized questionnaire structured into five parts was completed by ZaZiBoNa focal persons/nominated individuals to determine the experience of each NRA in addressing the safety and quality issues related to the presence of N-nitrosamine impurities in the affected medicines. Profiled medicines included sartans, ranitidine, metformin, rifampicin, and rifapentine. Results Sartan medicines had been reviewed by all countries participating in the ZaZiBoNa initiative. Although most NRAs have yet to conduct reviews on other profiled medicines, evaluations have been implemented to ensure access to safe and good quality medicines within the region. Most countries experienced challenges in communicating with applicants or marketing authorization holders (MAHs) on reviewing N-nitrosamine impurities in their medicines. The majority of NRAs agree that there is a need for further collaboration efforts to review N-nitrosamine impurities in medicines. Conclusion The review of N-nitrosamine impurities in the profiled medicines by NRAs within the region has demonstrated the importance of enhanced regulatory oversight to safeguard against the risks associated with medicines. Collaborative reliance on the review of the safety and quality of medicine, continuous monitoring, implementation and review of processes, testing methods, and regular engagements with stakeholders could be essential in ensuring adequate control of N-nitrosamine impurities in medicines.
Collapse
Affiliation(s)
- Patience P. Shabangu
- South African Health Products Regulatory Authority, Pharmaceutical Evaluations, Pretoria, South Africa
| | - Rutendo J. Kuwana
- Incidents and Substandard/Falsified Medical Products Team, Regulation and Safety of Medicines Unit, World Health Organization, Geneva, Switzerland
- *Correspondence: Rutendo J. Kuwana,
| | - Admire Dube
- School of Pharmacy, University of the Western Cape, Bellville, South Africa
- Admire Dube,
| |
Collapse
|
13
|
Evaluation of the Performance of the Gulf Cooperation Council Centralised Regulatory Review Process: Strategies to Improve Product Authorisation Efficiency and Quality. Pharmaceut Med 2022; 36:223-231. [PMID: 35767216 PMCID: PMC9334421 DOI: 10.1007/s40290-022-00432-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/01/2022] [Indexed: 12/05/2022]
Abstract
Background The Gulf Centralised Committee for Drug Registration (GCC-DR), as part of the Gulf Health Council (GHC), enables the consolidated registration of pharmaceutical products throughout the member states of the Gulf Cooperation Council. Objectives The objectives of this study were to provide an update of the performance of the GCC-DR centralised procedure; evaluate the review times for new products submitted to the GCC Centralised Registration between January 2015 and December 2020; assess the impact of applying facilitated regulatory pathways and implementing a reliance strategy; identify the strengths and weaknesses of the centralised review process; and propose strategies that could enhance the GCC regulatory review process leading to improved access to medicines for patients. Methods A standardised data collection template enabled the structured documentation of information collected by the Senior Regulatory Affairs and Regulatory Affairs Specialists from the Executive Board of the Health Ministers Council for GCC States to determine the GHC structure, resources, review models and milestones and timelines. The total number of applications approved was provided together with the average yearly timelines for new active substances and generics from January 2015 to December 2020 including both scientific assessment time from the agency as well as applicant response time to questions raised. Actual approval times for each product were calculated from the date of submission to the date of approval. Results The fewest (58) new products were approved in 2019 and the most (200) in 2020. The average review times for new medicines were the longest (838 calendar days) in 2015 and the shortest (321 calendar days) in 2019. Important changes recently implemented include an increase in the number of GCC-DR meetings, adoption of a standardised electronic common technical document and GCC regulatory review template, removal of authorisation dependence on pricing agreements and introduction of a reliance strategy. Additional recommendations include Executive Committee mandates for dossier review, target times for dossier validation, scientific review and Expert Committee recommendation and training for quality decision making. Conclusions GCC procedures and decision-making processes have been positively influenced by a variety of expert reviewers, unified guidelines and the implementation of a reliance strategy. Certain barriers must still be overcome to enhance the quality of the review, and to shorten regulatory review times without compromising the scientific robustness of the review.
Collapse
|
14
|
Sithole T, Mahlangu G, Walker S, Salek S. Regulatory Authority Evaluation of the Effectiveness and Efficiency of the ZaZiBoNa Collaborative Medicines Registration Initiative: The Way Forward. Front Med (Lausanne) 2022; 9:898743. [PMID: 35547217 PMCID: PMC9082034 DOI: 10.3389/fmed.2022.898743] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2022] [Accepted: 04/01/2022] [Indexed: 11/16/2022] Open
Abstract
Introduction ZaZiBoNa, the work-sharing initiative in the Southern African Development Community (SADC) that has been in operation for 8 years has successfully assessed over 300 dossiers/applications, with an overall median time to recommendation of 12 months. All 16 SADC countries participate in the initiative as either active or non-active members. While the successes of ZaZiBoNa are evident, some challenges still exist. The aim of this study was to solicit the views of the participating authorities on the effectiveness and efficiency of the current operating model of the ZaZiBoNa initiative. Methods Data were collected in 2021 using the Process, Effectiveness and Efficiency Rating (PEER) questionnaire developed by the authors. The questionnaire was completed by the focal person in each country and approved by the head of the authority. Results ZaZiBoNa serves as a platform for work sharing, information exchange, capacity building and harmonisation of registration requirements. One of the benefits to regulators has been the improvement in the capacity to conduct assessments. Manufacturers have benefited from compiling one package (modules 2–5) for the initial submission as well as a single response package to the consolidated list of questions, which saves time and resources. Respondents were of the view that patients have benefited as the ZaZiBoNa has contributed to an improved availability and accessibility to quality-assured medicines. Some of the challenges identified were the inadequacy of resources and differences in time to the implementation of ZaZiBoNa recommendations by the individual countries. The establishment of a regional unit hosted in one of the member countries to enable centralised submission and coordination was identified as the best strategy to improve the effectiveness and efficiency of the initiative in the interim, with the long-term goal being the establishment of a regional medicines authority. Conclusion The study identified the strengths of the ZaZiBoNa initiative as well as the opportunities for improvement. The recommendations made would further strengthen this initiative.
Collapse
Affiliation(s)
- Tariro Sithole
- School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom.,Medicines Control Authority of Zimbabwe, Harare, Zimbabwe
| | - Gugu Mahlangu
- Medicines Control Authority of Zimbabwe, Harare, Zimbabwe
| | - Stuart Walker
- School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom.,Centre for Innovation in Regulatory Science, London, United Kingdom
| | - Sam Salek
- School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom.,Institute for Medicines Development, Cardiff, United Kingdom
| |
Collapse
|
15
|
Sithole T, Mahlangu G, Walker S, Salek S. Pharmaceutical Industry Evaluation of the Effectiveness and Efficiency of the ZaZiBoNa Collaborative Medicines Registration Initiative: The Way Forward. Front Med (Lausanne) 2022; 9:898725. [PMID: 35547215 PMCID: PMC9082673 DOI: 10.3389/fmed.2022.898725] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2022] [Accepted: 04/01/2022] [Indexed: 11/20/2022] Open
Abstract
Introduction The common technical document (CTD) format harmonised the requirements for the registration of medicines, which had traditionally differed from country to country, making it possible for countries to collaborate and conduct joint reviews of applications. One such collaborative medicines registration initiative is the Southern African Development Community ZaZiBoNa, established in 2013. A recent study was carried out with the nine active member regulatory authorities of the ZaZiBoNa to determine their views on its operational effectiveness and efficiency. Having obtained the authorities' views, the aim of this study was to evaluate the effectiveness and efficiency of the current operating model of the ZaZiBoNa initiative including the challenges it faces as well as identifying opportunities for improvement from the applicants' perspective. Methods Applicants who had submitted registration/marketing authorisation applications for assessment under the ZaZiBoNa initiative during 2017-2021 were recruited into the study. Data was collected in 2021 using the Process, Effectiveness and Efficiency rating questionnaire (PEER-IND) developed by the authors. The questionnaire was completed by a representative responsible for ZaZiBoNa submissions in each company. Results The pharmaceutical industry was of the view that the ZaZiBoNa initiative has achieved shorter timelines for approval of medicines, resulting in increased availability of quality-assured medicines for patients in the SADC region. Harmonisation of registration requirements and joint reviews have reduced the workload for both the pharmaceutical industry and the regulatory authorities. Some of the challenges identified were the lack of a centralised submission and tracking system, and the lack of information for applicants on the process for submission of ZaZiBoNa dossiers/applications in the individual countries, including contact details of the focal person. The establishment of a regional unit hosted in one of the member countries to centrally receive and track ZaZiBoNa dossiers/applications was identified as the best strategy for moving forward in the interim with the long-term goal being the establishment of a regional medicines authority. Conclusion There was consensus between the pharmaceutical industry and the regulatory authorities as to the way forward to improve the effectiveness and efficiency of the ZaZiBoNa initiative. Implementation of the recommendations identified in this study will lead to enhanced regulatory performance.
Collapse
Affiliation(s)
- Tariro Sithole
- School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom
- Medicines Control Authority of Zimbabwe, Harare, Zimbabwe
| | - Gugu Mahlangu
- Medicines Control Authority of Zimbabwe, Harare, Zimbabwe
| | - Stuart Walker
- School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom
- Centre for Innovation in Regulatory Science (CIRS), London, United Kingdom
| | - Sam Salek
- School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom
- Institute for Medicines Development, Cardiff, United Kingdom
| |
Collapse
|
16
|
Ncube BM, Dube A, Ward K. Medicines Regulatory Science Expertise in Africa: Workforce Capacity Development and Harmonisation Activities Towards the Establishment of the African Medicines Agency. Pharmaceut Med 2022; 36:83-97. [DOI: 10.1007/s40290-022-00425-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/22/2022] [Indexed: 12/01/2022]
|
17
|
Moeti L, Litedu M, Joubert J. Common Deficiencies Found in the Active Pharmaceutical Ingredient (API) Section of Non-sterile Generic Products Submitted for Registration by SAHPRA. Ther Innov Regul Sci 2021; 56:276-290. [PMID: 34859393 DOI: 10.1007/s43441-021-00359-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2021] [Accepted: 11/17/2021] [Indexed: 12/12/2022]
Abstract
PURPOSE This research study aims to determine the qualitative and quantitative common deficiencies included in the API section of dossiers submitted to SAHPRA. The study was conducted retrospectively over a 7-year period (2011-2017) for non-sterile generic products that were finalised by the Pharmaceutical and Analytical pre-registration Unit. In this period, the restricted part of the CTD was evaluated when needed therefore this was not conducted on all applications. The requirement to evaluate the restricted part for all applications was initiated in January 2020, thus, a separate study has been conducted to identify the common deficiencies in the restricted part. METHODS There were 2089 applications finalised between 2011 and 2017 and in order to attain a representative sample for the study, the multi-stage statistical sampling called the 'stratified systematic sampling' was selected as the method of choice. Sample size was obtained using the statistical tables found in the literature and confirmed by a sample size calculation with a 95% confidence level, resulting in the selection of 325 applications. Subsequently, all the deficiencies were collected and categorised according to CTD subsections. For the restricted part study, all new applications evaluated between January to May 2020 were used. RESULTS A total of 1130 deficiencies were collected from 325 applications sampled. The majority of the identified deficiencies were from Module 3.2.S.3.1 (19.38%) on characterisation, Module 3.2.S.1.3 (19.11%) on general properties, Module 3.2.S.4.1 (10.44%) on specifications and Module 3.2.S.4.3 (8.32%) on validation of analytical methods. The study on the restricted parts included the five most common deficiencies that SAHPRA has identified, which are similar to those observed from the 2011-2017 applications. This confirms that the quality of the evaluations has been maintained over the years. Comparison of the deficiencies with those reported by other agencies such as the USFDA, EMA, WHOPQTm and TFDA are discussed with similarities clearly outlined. CONCLUSIONS The most common deficiencies observed by SAHPRA were extensively discussed. These findings could serve as a guidance for API manufacturers to submit better quality APIMFs which will improve turnaround times for registration and accelerate access to medicines for patients.
Collapse
Affiliation(s)
- Lerato Moeti
- South African Health Products Regulatory Authority (SAHPRA), Kirkness Street, Arcadia, Pretoria, 0007, South Africa.,School of Pharmacy, University of the Western Cape, Robert Sobukwe Road, Bellville, Cape Town, 7535, South Africa
| | - Madira Litedu
- South African Health Products Regulatory Authority (SAHPRA), Kirkness Street, Arcadia, Pretoria, 0007, South Africa
| | - Jacques Joubert
- School of Pharmacy, University of the Western Cape, Robert Sobukwe Road, Bellville, Cape Town, 7535, South Africa.
| |
Collapse
|
18
|
Palutturi S, Saleh LM, Rachmat M, Shabir AM, Rosmanely S, Aidillah MR, Malek JA, Nam EW. Inter-community Relations Factor on the Empowerment of the Aisle Community in Makassar City: A Structural Equation Model. Open Access Maced J Med Sci 2021. [DOI: 10.3889/oamjms.2021.7132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Background: There are several important factors in building community empowerment, one of them is the inter-community relationship. However, further research is rarely done on this dimension. The dimension of the relationship includes community structure, community strength, community motivation, community communication, community integrity, community participation, and community development. Objective: This study aimed to find the best model of the effect of the inter-community relationship on the condition of healthy aisle in Makassar City. Method: This research was conducted in 2 sub-districts in Makassar City, those are Rappocini District and Ujung Tanah District. The research samples involved were 560 households in Lorong. Data analysis was performed using multivariate analysis through the structural equation model (SEM) test. Results: The results of this study found that clear vision (CR = 3.219 and p = 0.01), capacity development (CR = 3.166 and p = 0.02), norms existence (CR = 3.143 and p = 0.02) on inter-community relationship significantly affected the aisle community empowerment. Conclusion: Inter-community relationship is the best model in developing a healthy aisle in Makassar City through solidarity, shared motivation, shared trust, clear vision, resources shares, capacity building, norms in society, government support, and community development. This study recommends that in order to maximize a clear vision for the aisle community working group, the government should carry out legality regarding the aisle community structure.
Collapse
|
19
|
Sithole T, Salek S, Mahlangu G, Walker S. Comparison of the registration process of the medicines control authority of Zimbabwe with Australia, Canada, Singapore, and Switzerland: benchmarking best practices. Expert Rev Clin Pharmacol 2021; 15:109-119. [PMID: 34645359 DOI: 10.1080/17512433.2022.1987883] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND Benchmarking regulatory systems of low- and middle-income countries with mature systems provides an opportunity to identify gaps, enhance review quality, and reduce registration timelines, thereby improving patients' access to medicines. The aim of this study was to compare the medicines registration process of the Medicines Control Authority of Zimbabwe (MCAZ) with the regulatory processes in Australia, Canada, Singapore, and Switzerland. METHODS A questionnaire that standardizes the review process, allowing key milestones, activities and practices of the five regulatory authorities was completed by a senior member of the divisions responsible for issuing marketing authorizations. RESULTS The MCAZ has far fewer resources than the regulatory authorities in the comparator countries, but employs three review models, which is in line with international best practice. The MCAZ registration process is similar to the comparator countries in key milestones monitored, but differs in the target timelines for these milestones. The MCAZ is comparable to the comparator authorities in implementing the majority of good review practices, although it significantly lags behind in transparency and communication. CONCLUSION This study identified the MCAZ strengths and opportunities for improvement, which if implemented, will enable the achievement of its vision to be a leading regulatory authority in Africa.
Collapse
Affiliation(s)
- Tariro Sithole
- School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK.,Medicines Control Authority of Zimbabwe, Zimbabwe
| | - Sam Salek
- School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK.,Institute for Medicines Development, Cardiff, UK
| | | | - Stuart Walker
- School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK.,Centre for Innovation in Regulatory Science (Cirs), London, UK
| |
Collapse
|
20
|
Sithole T, Mahlangu G, Capote V, Sitoie T, Shifotoka S, Gaeseb J, Padayachee S, Sehloho T, Khea A, Fimbo A, Munkombwe Z, Mwale B, Salek S, Walker S. Evaluation of the Good Review Practices of Countries Participating in the Southern African Development Community: Alignment and Strategies for Moving Forward. Front Med (Lausanne) 2021; 8:742181. [PMID: 34513893 PMCID: PMC8429788 DOI: 10.3389/fmed.2021.742181] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Accepted: 08/06/2021] [Indexed: 11/13/2022] Open
Abstract
Introduction: National medicines regulatory agencies are faced with challenges including limited resources and technical capacity, resulting in countries collaborating and sharing resources to improve efficiency of the review process to facilitate access to quality-assured medicines by their populations. One such collaboration is the Southern African Development Community (SADC) medicines registration collaborative initiative, ZaZiBoNa. Countries participate in the initiative by contributing to regulatory reviews and good manufacturing practices inspections. The aim of this study was to review and compare the registration processes of regulatory authorities of Mozambique, Namibia, South Africa, Tanzania, Zambia, and Zimbabwe to identify strategies for better alignment. Methods: A senior member of the division responsible for issuing marketing authorisations completed an established and validated questionnaire, which standardises the review process, allowing key milestones, activities and practices of the six regulatory authorities to be identified and compared. The completed questionnaires were validated by the heads of the respective agencies. Results: The six countries vary in population and in the size of their respective regulatory agency and the resources allocated to regulatory reviews. The review processes of the six agencies were similar; however, differences were noted in the milestones recorded; for example, two of the countries did not record the start of the scientific assessment. Additionally, decisions for marketing authorisation were made by an expert committee in four of the countries and by the head of the agency and the Minister of Health in two countries. All six agencies implemented the majority of good review practices; however, the need for improvement in the areas of transparency and communication and quality decision making practices was a common finding for all six countries. Conclusions: Participation in the ZaZiBoNa initiative has improved the way in which the six agencies perform regulatory reviews in their countries, highlighting the realisation of one of the key objectives of the initiative, which was building the expert capacity of member countries. Other agencies in the SADC region and beyond can use the results of this study to identify best practices, which in turn, could improve their regulatory performance.
Collapse
Affiliation(s)
- Tariro Sithole
- School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom
- Medicines Control Authority of Zimbabwe, Harare, Zimbabwe
| | - Gugu Mahlangu
- Medicines Control Authority of Zimbabwe, Harare, Zimbabwe
| | - Velma Capote
- National Directorate of Pharmacy, Mozambique Ministry of Health, Maputo, Mozambique
| | - Tania Sitoie
- National Directorate of Pharmacy, Mozambique Ministry of Health, Maputo, Mozambique
| | - Saren Shifotoka
- Namibia Medicines Regulatory Council, Namibia Ministry of Health and Social Services, Windhoek, Namibia
| | - Johannes Gaeseb
- Namibia Medicines Regulatory Council, Namibia Ministry of Health and Social Services, Windhoek, Namibia
| | | | - Tohlang Sehloho
- South African Health Products Regulatory Authority, Pretoria, South Africa
| | - Akida Khea
- Tanzania Medicines and Medical Devices Authority, Dodoma, Tanzania
| | - Adam Fimbo
- Tanzania Medicines and Medical Devices Authority, Dodoma, Tanzania
| | | | - Bernice Mwale
- Zambia Medicines Regulatory Authority, Lusaka, Zambia
| | - Sam Salek
- School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom
- Institute for Medicines Development, Cardiff, United Kingdom
| | - Stuart Walker
- School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom
- Centre for Innovation in Regulatory Science, London, United Kingdom
| |
Collapse
|
21
|
Semete-Makokotlela B, Mahlangu GN, Mukanga D, Darko DM, Stonier P, Gwaza L, Nkambule P, Matsoso P, Lehnert R, Rosenkranz B, Pillai GC. Needs-driven talent and competency development for the next generation of regulatory scientists in Africa. Br J Clin Pharmacol 2021; 88:579-586. [PMID: 34346098 PMCID: PMC9291465 DOI: 10.1111/bcp.15020] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2021] [Revised: 05/18/2021] [Accepted: 07/09/2021] [Indexed: 12/13/2022] Open
Abstract
Capacity building programmes for African regulators should link education, training and research with career development in an approach that combines an academic base and experiential learning aligned within a competency framework. A regulatory ecosystem that engages with a broad range of stakeholders will mean that expertise in the ever‐expanding field of regulatory science filters into teaching and research in a symbiotic way. In this way capacity development interventions will be a collaborative approach between the learning context (academic and training institutions) and the performance context (regulatory agencies and industry), which will ultimately best serve the patients. Monitoring and evaluation of capacity development interventions will be essential to show value of investments and ultimately guide continued funding and sustainability. This paper reviews the skills and human capacity gaps, reports on regulatory assessment pathways used in Ghana, South Africa and Zimbabwe and outlines a staged tactical approach for Africa that builds on previous efforts to strengthen African regulatory ecosystems.
Collapse
Affiliation(s)
| | | | | | | | - Peter Stonier
- Pharmaceutical Medicine Department, Institute of Pharmaceutical Sciences, Faculty of Health Sciences and Medicine, Kings College London, UK
| | | | - Portia Nkambule
- South African Health Products Regulatory Authority, Pretoria, Gauteng, South Africa
| | - Precious Matsoso
- Department of Pharmacy & Pharmacology, Faculty of Sciences, University of the Witwatersrand, South Africa
| | - Regine Lehnert
- GHPP-PharmTrain project, Federal Institute for Drugs and Medical Devices (BfArM), Germany
| | - Bernd Rosenkranz
- Fundisa African Academy of Medicines Development, Cape Town, South Africa.,Division of Clinical Pharmacology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
| | - Goonaseelan Colin Pillai
- Division of Clinical Pharmacology, University of Cape Town, South Africa.,CP+ Associates GmbH, Basel, Switzerland.,Pharmacometrics Africa NPC, Cape Town, South Africa
| |
Collapse
|
22
|
Ncube BM, Dube A, Ward K. Establishment of the African Medicines Agency: progress, challenges and regulatory readiness. J Pharm Policy Pract 2021; 14:29. [PMID: 33685518 PMCID: PMC7938385 DOI: 10.1186/s40545-020-00281-9] [Citation(s) in RCA: 36] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2020] [Accepted: 12/01/2020] [Indexed: 12/15/2022] Open
Abstract
Insufficient access to quality, safe, efficacious and affordable medical products in Africa has posed a significant challenge to public health for decades. In part, this is attributed to weak or absent policies and regulatory systems, a lack of competent regulatory professionals in National Medicines Regulatory Authorities (NMRAs) and ineffective regional collaborations among NMRAs. In response to national regulatory challenges in Africa, a number of regional harmonisation efforts were introduced through the African Medicines Regulatory Harmonisation (AMRH) initiative to, among others, expedite market authorisation of medical products and to facilitate the alignment of national legislative frameworks with the AU Model Law on Medical Products Regulation. The goals of the model law include to increase collaboration across countries and to facilitate the overall regional harmonisation process. The AMRH initiative is proposed to serve as the foundation for the establishment of the African Medicines Agency (AMA). The AMA will, as one of its mandates, coordinate the regional harmonisation systems that are enabled by AU Model Law domestication and implementation. In this paper, we review the key entities involved in regional and continental harmonisation of medicines regulation, the milestones achieved in establishing the AMA as well as the implementation targets and anticipated challenges related to the AU Model Law domestication and the AMA's establishment. This review shows that implementation targets for the AU Model Law have not been fully met, and the AMA treaty has not been ratified by the minimum required number of countries for its establishment. In spite of the challenges, the AU Model Law and the AMA hold promise to address gaps and inconsistencies in national regulatory legislation as well as to ensure effective medicines regulation by galvanising technical support, regulatory expertise and resources at a continental level. Furthermore, this review provides recommendations for future research.
Collapse
Affiliation(s)
- Bakani Mark Ncube
- Department of Pharmacy Practice, School of Pharmacy, University of the Western Cape, Private Bag X17, Bellville, 7535, South Africa
| | - Admire Dube
- Department of Pharmacy Practice, School of Pharmacy, University of the Western Cape, Private Bag X17, Bellville, 7535, South Africa
| | - Kim Ward
- Department of Pharmacy Practice, School of Pharmacy, University of the Western Cape, Private Bag X17, Bellville, 7535, South Africa.
| |
Collapse
|
23
|
Sithole T, Mahlangu G, Salek S, Walker S. Evaluation of the Regulatory Review Process in Zimbabwe: Challenges and Opportunities. Ther Innov Regul Sci 2021; 55:474-489. [PMID: 33387356 PMCID: PMC8021537 DOI: 10.1007/s43441-020-00242-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2020] [Accepted: 11/10/2020] [Indexed: 12/12/2022]
Abstract
Purpose The aims of this study were to assess the current regulatory review process of the Medicines Control Authority of Zimbabwe (MCAZ), identify key milestones and target timelines, evaluate the overall performance from 2017 to 2019, identify good review practices, evaluate the quality of decision-making processes, and identify the challenges and opportunities for improvement. Methods A questionnaire was completed by the MCAZ. The agency has participated in the Optimising Efficiencies in Regulatory Agencies (OpERA) program, a multinational endeavor to characterize assessment procedures and metrics associated with regulatory agencies and regional regulatory initiatives. Data identifying the milestones and overall approval times for all products registered MCAZ from 2017 to 2019 were collected and analyzed. Results The MCAZ conducts a full review of quality, safety, and efficacy data for generics and biosimilars not approved by a reference agency, an abridged review for products approved by a reference agency and a verification review for World Health Organization prequalified products under the collaborative registration procedure. The highest number of reviewed products is generics manufactured by foreign companies. There has been an improvement in review times for all categories of products over the three-year period. Guidelines, standard operating procedures, and review templates are in place and the majority of indicators for good review practices are implemented. Although quality decision-making practices are implemented, there is no formal framework in place. Conclusion The MCAZ successfully implements three types of review models in line with international standards. Overall, target timelines are realistic and what is achievable with the current available resources. Recommendations made such as the review of available human resources, separation of agency and company time when setting and measuring targets, review of the templates and benefit-risk framework used for abridged review, and development of a decision-making framework present opportunities for an enhanced regulatory review process.
Collapse
Affiliation(s)
- Tariro Sithole
- School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK.,Medicines Control Authority of Zimbabwe, Harare, Zimbabwe
| | - Gugu Mahlangu
- Medicines Control Authority of Zimbabwe, Harare, Zimbabwe
| | - Sam Salek
- School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK.,Institute of Medicines Development, Cardiff, UK
| | - Stuart Walker
- School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK. .,Centre for Innovation in Regulatory Science, 160 Blackfriars Road, London, SE1 8EZ, UK.
| |
Collapse
|